Scarica l'app Stockscreener
0.5294
5.80%
0.029
Dopo l'orario di chiusura:
.52
-0.0094
-1.78%
Io Biotech Inc Borsa (IOBT) Ultime notizie
Multi asset correlation models including IO Biotech Inc.Market Performance Recap & Growth Oriented Trading Recommendations - newser.com
Layoff Tracker: Novo’s Cuts Leave Dozens of Manufacturing Workers Jobless - BioSpace
Tick level data insight on IO Biotech Inc. volatilityEarnings Beat & Risk Controlled Swing Trade Alerts - newser.com
How IO Biotech Inc. stock reacts to global recession fearsEntry Point & Safe Capital Growth Trade Ideas - newser.com
How sentiment analysis helps forecast IO Biotech Inc.Earnings Performance Report & Risk Managed Trade Strategies - newser.com
What does recent volatility data suggest for IO Biotech Inc.July 2025 Setups & Consistent Growth Equity Picks - newser.com
Analysts Set IO Biotech, Inc. (NASDAQ:IOBT) Price Target at $8.00 - Defense World
Applying chart zones and confluence areas to IO Biotech Inc.Portfolio Update Summary & Long-Term Safe Investment Plans - newser.com
IO Biotech’s (IOBT) Hold Rating Reaffirmed at TD Cowen - Defense World
IO Biotech (IOBT) Downgraded to Hold by TD Cowen | IOBT Stock Ne - GuruFocus
IO Biotech Faces Setback as FDA Opposes Cylembio BLA Submission, Morgan Stanley Says - MarketScreener
IO Biotech Feels The Heat As US FDA Dashes Cylembio Filing Hopes - insights.citeline.com
IO Biotech (NASDAQ:IOBT) Receives "Hold" Rating from TD Cowen - MarketBeat
IO Biotech (NASDAQ:IOBT) Downgraded to Equal Weight Rating by Morgan Stanley - MarketBeat
TD Cowen Maintains IO Biotech(IOBT.US) With Hold Rating - 富途牛牛
TD Cowen Downgrades IO Biotech to Hold From Buy - MarketScreener
FDA Recommends Against IO Biotech’s Cylembio Application - The Globe and Mail
Morgan Stanley Downgrades IO Biotech to Equalweight From Overweight, Cuts Price Target to $0.39 From $4 - MarketScreener
IO Biotech (NASDAQ:IOBT) Downgraded by HC Wainwright to “Neutral” - Defense World
IO Biotech stock rating downgraded to Hold by TD Cowen on FDA setback - Investing.com Canada
IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine - NewsBreak: Local News & Alerts
IO Biotech stock downgraded to Neutral by H.C. Wainwright on trial delays - Investing.com Canada
IOBT Downgraded to Neutral by HC Wainwright & Co. | IOBT Stock News - GuruFocus
IO Biotech drops after FDA recommends another late-stage study for cancer vaccine - TradingView
IO Biotech stock plummets after FDA recommends against BLA submission By Investing.com - Investing.com Australia
IO Biotech stock plummets after FDA recommends against BLA submission - Investing.com India
IO Biotech Advised Against Filing Biologics License Application for Cylembio; Plans to Cut 50% of Workforce - MarketScreener
Nasdaq Jumps 150 Points; US Pending Home Sales Rise - Benzinga
FDA recommends against IO Biotech’s BLA for melanoma vaccine By Investing.com - Investing.com Canada
Io Biotech Announces Restructuring Plan, Plans Global Workforce Reduction of ~50% with One-Time Charges of $1?1.5 Million - MarketScreener
0.74%
1.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):